170 related articles for article (PubMed ID: 30683020)
1. The Bromodomain and Extra-Terminal Protein Inhibitor OTX015 Suppresses T Helper Cell Proliferation and Differentiation.
Hu X; Schewitz-Bowers LP; Lait PJP; Copland DA; Stimpson ML; Li JJ; Liu Y; Dick AD; Lee RWJ; Wei L
Curr Mol Med; 2018; 18(9):594-601. PubMed ID: 30683020
[TBL] [Abstract][Full Text] [Related]
2. The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs.
Boi M; Gaudio E; Bonetti P; Kwee I; Bernasconi E; Tarantelli C; Rinaldi A; Testoni M; Cascione L; Ponzoni M; Mensah AA; Stathis A; Stussi G; Riveiro ME; Herait P; Inghirami G; Cvitkovic E; Zucca E; Bertoni F
Clin Cancer Res; 2015 Apr; 21(7):1628-38. PubMed ID: 25623213
[TBL] [Abstract][Full Text] [Related]
3. OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models.
Berenguer-Daizé C; Astorgues-Xerri L; Odore E; Cayol M; Cvitkovic E; Noel K; Bekradda M; MacKenzie S; Rezai K; Lokiec F; Riveiro ME; Ouafik L
Int J Cancer; 2016 Nov; 139(9):2047-55. PubMed ID: 27388964
[TBL] [Abstract][Full Text] [Related]
4. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
[TBL] [Abstract][Full Text] [Related]
5. The BET Inhibitor OTX015 Exhibits In Vitro and In Vivo Antitumor Activity in Pediatric Ependymoma Stem Cell Models.
Servidei T; Meco D; Martini M; Battaglia A; Granitto A; Buzzonetti A; Babini G; Massimi L; Tamburrini G; Scambia G; Ruggiero A; Riccardi R
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33668642
[TBL] [Abstract][Full Text] [Related]
6. BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells.
Coudé MM; Braun T; Berrou J; Dupont M; Bertrand S; Masse A; Raffoux E; Itzykson R; Delord M; Riveiro ME; Herait P; Baruchel A; Dombret H; Gardin C
Oncotarget; 2015 Jul; 6(19):17698-712. PubMed ID: 25989842
[TBL] [Abstract][Full Text] [Related]
7. Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition.
Henssen A; Althoff K; Odersky A; Beckers A; Koche R; Speleman F; Schäfers S; Bell E; Nortmeyer M; Westermann F; De Preter K; Florin A; Heukamp L; Spruessel A; Astrahanseff K; Lindner S; Sadowski N; Schramm A; Astorgues-Xerri L; Riveiro ME; Eggert A; Cvitkovic E; Schulte JH
Clin Cancer Res; 2016 May; 22(10):2470-81. PubMed ID: 26631615
[TBL] [Abstract][Full Text] [Related]
8. BET Bromodomain Inhibition Suppresses Human T Cell Function.
Georgiev P; Wang Y; Muise ES; Bandi ML; Blumenschein W; Sathe M; Pinheiro EM; Shumway SD
Immunohorizons; 2019 Jul; 3(7):294-305. PubMed ID: 31356159
[TBL] [Abstract][Full Text] [Related]
9. Selective inhibition of CD4+ T-cell cytokine production and autoimmunity by BET protein and c-Myc inhibitors.
Bandukwala HS; Gagnon J; Togher S; Greenbaum JA; Lamperti ED; Parr NJ; Molesworth AM; Smithers N; Lee K; Witherington J; Tough DF; Prinjha RK; Peters B; Rao A
Proc Natl Acad Sci U S A; 2012 Sep; 109(36):14532-7. PubMed ID: 22912406
[TBL] [Abstract][Full Text] [Related]
10. OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations.
Riveiro ME; Astorgues-Xerri L; Vazquez R; Frapolli R; Kwee I; Rinaldi A; Odore E; Rezai K; Bekradda M; Inghirami G; D'Incalci M; Noel K; Cvitkovic E; Raymond E; Bertoni F
Oncotarget; 2016 Dec; 7(51):84675-84687. PubMed ID: 27835869
[TBL] [Abstract][Full Text] [Related]
11. Targeted Therapy of
Chen J; Nelson C; Wong M; Tee AE; Liu PY; La T; Fletcher JI; Kamili A; Mayoh C; Bartenhagen C; Trahair TN; Xu N; Jayatilleke N; Wong M; Peng H; Atmadibrata B; Cheung BB; Lan Q; Bryan TM; Mestdagh P; Vandesompele J; Combaret V; Boeva V; Wang JY; Janoueix-Lerosey I; Cowley MJ; MacKenzie KL; Dolnikov A; Li J; Polly P; Marshall GM; Reddel RR; Norris MD; Haber M; Fischer M; Zhang XD; Pickett HA; Liu T
Clin Cancer Res; 2021 Mar; 27(5):1438-1451. PubMed ID: 33310889
[TBL] [Abstract][Full Text] [Related]
12. The CDK4/6-UCHL5-BRD4 axis confers resistance to BET inhibitors in MLL-rearranged leukemia cells by suppressing BRD4 protein degradation.
Amari K; Sasagawa S; Imayoshi N; Toda Y; Hosogi S; Imamura T; Ashihara E
Biochem Biophys Res Commun; 2022 Jan; 588():147-153. PubMed ID: 34954522
[TBL] [Abstract][Full Text] [Related]
13. T-bet over-expression regulates aryl hydrocarbon receptor-mediated T helper type 17 differentiation through an interferon (IFN)γ-independent pathway.
Yokosawa M; Kondo Y; Tahara M; Iizuka-Koga M; Segawa S; Kaneko S; Tsuboi H; Yoh K; Takahashi S; Matsumoto I; Sumida T
Clin Exp Immunol; 2017 Apr; 188(1):22-35. PubMed ID: 27936495
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-2 down-modulates memory T helper lymphocyte development during antigenic stimulation in vitro.
Bemer V; Motta I; Perret R; Truffa-Bachi P
Eur J Immunol; 1995 Dec; 25(12):3394-401. PubMed ID: 8566029
[TBL] [Abstract][Full Text] [Related]
15. Potent Activity of the Bromodomain Inhibitor OTX015 in Multiple Myeloma.
Shi J; Song S; Han H; Xu H; Huang M; Qian C; Zhang X; Ouyang L; Hong Y; Zhuang W; Li B
Mol Pharm; 2018 Sep; 15(9):4139-4147. PubMed ID: 30048594
[TBL] [Abstract][Full Text] [Related]
16. Expansion of T follicular helper-T helper 1 like cells through epigenetic regulation by signal transducer and activator of transcription factors.
Ma X; Nakayamada S; Kubo S; Sakata K; Yamagata K; Miyazaki Y; Yoshikawa M; Kitanaga Y; Zhang M; Tanaka Y
Ann Rheum Dis; 2018 Sep; 77(9):1354-1361. PubMed ID: 29853448
[TBL] [Abstract][Full Text] [Related]
17. A monocyte-keratinocyte-derived co-culture assay accurately identifies efficacies of BET inhibitors as therapeutic candidates for psoriasiform dermatitis.
Wu X; Shi Z; Hsu DK; Chong J; Huynh M; Mendoza L; Yamada D; Hwang ST
J Dermatol Sci; 2020 Oct; 100(1):31-38. PubMed ID: 32900573
[TBL] [Abstract][Full Text] [Related]
18. Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphoma.
Mensah AA; Cascione L; Gaudio E; Tarantelli C; Bomben R; Bernasconi E; Zito D; Lampis A; Hahne JC; Rinaldi A; Stathis A; Zucca E; Kwee I; Gattei V; Valeri N; Riveiro ME; Bertoni F
Haematologica; 2018 Dec; 103(12):2049-2058. PubMed ID: 30076183
[TBL] [Abstract][Full Text] [Related]
19. IFN-beta inhibits human Th17 cell differentiation.
Ramgolam VS; Sha Y; Jin J; Zhang X; Markovic-Plese S
J Immunol; 2009 Oct; 183(8):5418-27. PubMed ID: 19783688
[TBL] [Abstract][Full Text] [Related]
20. T-bet inhibits the in vivo differentiation of parasite-specific CD4+ Th17 cells in a T cell-intrinsic manner.
Guo S; Cobb D; Smeltz RB
J Immunol; 2009 May; 182(10):6179-86. PubMed ID: 19414771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
